Clinical trial

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

NCT02834247

Study summary

ClinicalTrials.gov

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention TAK-659 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Nivolumab Normalized identity: nivolumab View linked drug · Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2016-08-12

PhasePHASE1

Conditions

Triple-Negative Breast Neoplasmsunresolved

Carcinoma, Non-Small-Cell Lungunresolved

Head and Neck Carcinoma, Squamous Cellunresolved

Advanced Solid Tumorsunresolved

Interventions

TAK-659DRUG

NivolumabDRUG · verified · RxNorm: nivolumab

Sponsors & collaborators

Calithera Biosciences, Inclead sponsor

Mapped research locations

MadridSpain2 MilanItaly2 ValenciaSpain2 BostonMassachusetts, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 AtlantaGeorgia, United States1 NashvilleTennessee, United States1 DetroitMichigan, United States1 La JollaCalifornia, United States1 BuffaloNew York, United States1 MálagaSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02834247 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.